`Aq11ebogue,N.Y. 11931
`: 531.72zs9ss « Fax: 631.722.9683
`
`i ii I Pha1maoeutica1s.Inc.
`
`VIA UPS OVERNIGHT
`
`March 26, 2014
`
`s, 2014
`
`ncr In 0.7 1.35
`
`#PK 1
`
`éggizltfificu i1:iai4'Ei‘4E01Bi'46L"IT53921 '0 LBSRLL CURRENCY “SD
`Paragon Bidreck’ hm
`PURCHQSE No, ;
`|_nuREN ncméusrr
`4640 SW Macadam Avenue, Suite 80
`am
`RT
`REF 2:PnRAGON arorzcu ru .
`Portland, OR 97239
`cNs 0.00
`-
`'
`svc Rgp 5530
`Attn. Lauren McBluett, Director ofQual1ty Assuram gfilafigg; PUB mm cmgggsz 0 no
`-
`0
`ov
`.
`ROD
`0.00
`RE:
`Phenylephrine HCL Ophthalmic Solution,; DC 0-:3
`3:0
`gig;
`‘iiir onus CH6 0.00
`PUB+HnNDLING
`0.00
`
`°
`
`F
`
`=
`
`Dear Ms. McBluett:
`
`4
`
`As requested, enclosed please find a “Confidential pup)’ o1 A1ta1re"s report b"l'UO346- “Method
`Validation Report for Qualitative Chiral Purity of Phenylephrine HCL in Phenylephrine HCl
`Ophthalmic Solution, USP (2.5% and 10%).”
`
`Please note that the enclosedis the proprietary and confidential information ofAltaire and is
`provided for the‘ limited purposes of
`the filing of annual report of an NDA for
`Phenylephrine HCI Ophthalmic Solution, USP (2.5% and 10%) specifying Altaire as the manufacturer.
`
`Paragon may not provide any copies ofthe enclosed documents to any third party without the
`express written consent of Altaire.
`
`By providing these copies, Altaire does not grant Paragon any right or license to said documents.
`
`Very truly yours,
`
`/fig
`
`Michae Sawaya
`General Counsel
`
`'
`
`MSS/gf
`Enclosures as indicated
`
`Exhibit 1031, Page 1 of1
`
`Exhibit 1031, Page 1 of 1